Torrent Pharma.
Drug Manufacturers - Specialty & Generic · TORNTPHARM
Mega CapHealthcareMature Stable
Aman Mehta
Managing Director · Pragmatic
Company DNA
Hierarchical
About
Torrent Pharma. is a Mega Cap company in the Healthcare sector, listed on NSE as TORNTPHARM. With a market cap of ₹148K Cr and revenue of ₹11K Cr, it is currently in the Mature Stable phase. Known for its Hierarchical culture and Fast-Follower approach to innovation, the company operates at a Steady-Marathon pace. A long-established family-promoted firm where decision-making remains centralized at the promoter level, maintaining a structured, formal, and traditional corporate governance approach. Its strategic mandate: Focus must shift towards specialized R&D and portfolio diversification to offset pricing pressures in generic markets.
FAQ
What kind of company is Torrent Pharma.?
Torrent Pharma. is a Mega Cap Healthcare company (TORNTPHARM) in the Mature Stable phase with a market cap of ₹148K Cr. It is classified as Hierarchical in culture.
What is Torrent Pharma.'s culture and work environment like?
Torrent Pharma. has a Hierarchical culture with Fast-Follower innovation DNA and a Steady-Marathon pace of execution. Employee brand: Steady Employer. Customer relationship style: B2B-Enterprise. A long-established family-promoted firm where decision-making remains centralized at the promoter level, maintaining a structured, formal, and traditional corporate governance approach.
Who leads Torrent Pharma.?
Torrent Pharma. is led by Aman Mehta (Managing Director), a Pragmatic leader with 13 years of experience.
What are Torrent Pharma.'s financials?
Torrent Pharma. reported revenue of ₹11K Cr in FY25 with a 5-year revenue CAGR of 10.4%. Operating margin: 25.9%. Market cap: ₹148K Cr.
Culture & Strategy
CultureHierarchical
InnovationFast-Follower
PaceSteady-Marathon
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployeeSteady Employer
BrandTrusted
LifecycleMature Stable
A long-established family-promoted firm where decision-making remains centralized at the promoter level, maintaining a structured, formal, and traditional corporate governance approach.
Mandate
Focus must shift towards specialized R&D and portfolio diversification to offset pricing pressures in generic markets.
Focus must shift towards specialized R&D and portfolio diversification to offset pricing pressures in generic markets.
Financials
Revenue FY25₹11K Cr
PAT FY25₹2K Cr
Rev CAGR 5Y10.4%
OPM25.9%
NPM16.9%
ROE25.2%
ROCE28.5%
P/E65.4
Fwd P/E68.8
P/B—
D/E33.4
Mkt Cap₹148K Cr
Promoter71.1%
Institutional14.6%
Similar Culture
Could You Lead Torrent Pharma.?
Take the Genome Benchmark →